Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Lung Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
80 drugs · 288 active trials
21 drugs · 611 active trials
51 drugs · 1,372 active trials
Outside the funnel: Phase not stated 2 · Withdrawn 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 7 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Adebrelimab | Phase 3 | Phase 3 | 25 | 7 | 3 | 29 | 0 | — | — | Dec 30, 2018 |
| Sintilimab | Phase 3 | Phase 3 | 20 | 12 | 4 | 47 | 0 | — | — | Sep 1, 2017 |
| Cyclophosphamide | Phase 3 | Phase 3 | 19 | 11 | 7 | 66 | 0 | — | — | 1991-04 |
| Toripalimab | Phase 3 | Phase 3 | 19 | 10 | 6 | 37 | 0 | — | — | 2016-08 |
| Cetuximab | Phase 3 | Phase 3 | 18 | 12 | 5 | 84 | 0 | — | — | 2000-12 |
| Serplulimab | Phase 3 | Phase 3 | 15 | 9 | 3 | 21 | 0 | — | — | Sep 12, 2019 |
| Sunvozertinib | Phase 3 | Phase 3 | 12 | 8 | 2 | 12 | 0 | — | — | Jul 9, 2019 |
| Olaparib | Phase 3 | Phase 3 | 10 | 2 | 2 | 24 | 0 | — | — | 2011-08 |
| Immunotherapy | Phase 3 | Phase 3 | 10 | 7 | 4 | 22 | 0 | — | — | Mar 10, 2017 |
| Sacituzumab Govitecan | Phase 3 | Phase 3 | 9 | 3 | 4 | 13 | 0 | — | — | Dec 17, 2012 |
| Oxaliplatin | Phase 3 | Phase 3 | 8 | 3 | 1 | 27 | 0 | — | — | 1999-11 |
| Cabozantinib | Phase 3 | Phase 3 | 8 | 3 | 1 | 19 | 0 | — | — | Feb 12, 2008 |
| Fluorouracil | Phase 3 | Phase 3 | 8 | 4 | 1 | 17 | 0 | — | — | 1990-09 |
| Divarasib | Phase 3 | Phase 3 | 7 | 4 | 4 | 7 | 0 | — | — | Sep 22, 2017 |
| Temozolomide | Phase 3 | Phase 3 | 6 | 2 | 2 | 28 | 0 | — | — | 1997-07 |
| Leucovorin | Phase 3 | Phase 3 | 6 | 2 | 1 | 13 | 0 | — | — | 1998-08 |
| Dostarlimab | Phase 3 | Phase 3 | 5 | 0 | 2 | 9 | 0 | — | — | Oct 12, 2017 |
| Savolitinib | Phase 3 | Phase 3 | 5 | 2 | 1 | 9 | 0 | — | — | 2015-04 |
| Cobimetinib | Phase 3 | Phase 3 | 5 | 2 | 2 | 8 | 0 | — | — | Jun 16, 2015 |
| Filgrastim | Phase 3 | Phase 3 | 4 | 1 | 5 | 23 | 0 | — | — | 1997-09 |
| Brigatinib | Phase 3 | Phase 3 | 4 | 0 | 1 | 17 | 0 | — | — | Sep 20, 2011 |
| Carboplatin/Paclitaxel Regimen | Phase 3 | Phase 3 | 4 | 2 | 7 | 17 | 0 | — | — | 2003-03 |
| Amrubicin | Phase 3 | Phase 3 | 4 | 3 | 8 | 15 | 0 | — | — | 2004-05 |
| Abemaciclib | Phase 3 | Phase 3 | 4 | 1 | 1 | 12 | 0 | — | — | Jul 31, 2012 |
| Ipilimumab/Nivolumab Regimen | Phase 3 | Phase 3 | 4 | 2 | 1 | 7 | 0 | — | — | Apr 13, 2017 |
| Selumetinib | Phase 3 | Phase 3 | 3 | 0 | 1 | 23 | 0 | — | — | 2006-08 |
| Avelumab | Phase 3 | Phase 3 | 3 | 1 | 3 | 22 | 0 | — | — | Mar 24, 2015 |
| Metformin | Phase 3 | Phase 3 | 3 | 2 | 1 | 16 | 0 | — | — | 2008-03 |
| Lenvatinib | Phase 3 | Phase 3 | 3 | 0 | 4 | 14 | 0 | — | — | 2009-02 |
| Veliparib | Phase 3 | Phase 3 | 3 | 0 | 2 | 14 | 0 | — | — | 2011-01 |
| Capecitabine | Phase 3 | Phase 3 | 3 | 1 | 1 | 13 | 0 | — | — | 2004-12 |
| Talazoparib | Phase 3 | Phase 3 | 3 | 0 | 1 | 10 | 0 | — | — | Jan 3, 2011 |
| Niraparib | Phase 3 | Phase 3 | 3 | 1 | 1 | 8 | 0 | — | — | Aug 29, 2017 |
| Vemurafenib | Phase 3 | Phase 3 | 3 | 2 | 2 | 5 | 0 | — | — | May 12, 2017 |
| Ceritinib | Phase 3 | Phase 3 | 2 | 0 | 2 | 18 | 0 | — | — | Jan 24, 2011 |
| Cediranib | Phase 3 | Phase 3 | 2 | 0 | 2 | 15 | 0 | — | — | Jan 21, 2005 |
| Palbociclib | Phase 3 | Phase 3 | 2 | 1 | 1 | 12 | 0 | — | — | 2011-02 |
| TAK-788 | Phase 3 | Phase 3 | 2 | 0 | 1 | 4 | 0 | — | — | Jun 16, 2016 |
| Adjuvant Chemotherapy | Phase 3 | Phase 3 | 2 | 0 | 1 | 3 | 0 | — | — | 1999-09 |
| Camrelizumab | Phase 3 | Phase 3 | 1 | 0 | 5 | 30 | 0 | — | — | Mar 13, 2017 |
| Doxorubicin | Phase 3 | Phase 3 | 1 | 1 | 5 | 15 | 0 | — | — | 1993-01 |
| Vorinostat | Phase 3 | Phase 3 | 1 | 0 | 1 | 15 | 0 | — | — | 2005-06 |
| Aspirin | Phase 3 | Phase 3 | 1 | 0 | 2 | 8 | 0 | — | — | 2010-08 |
| Tretinoin | Phase 3 | Phase 3 | 1 | 1 | 1 | 8 | 0 | — | — | 1998-09 |
| Mitomycin | Phase 3 | Phase 3 | 1 | 1 | 5 | 7 | 0 | — | — | 1995-10 |
| Axitinib | Phase 3 | Phase 3 | 1 | 0 | 1 | 6 | 0 | — | — | 2005-02 |
| Retifanlimab | Phase 3 | Phase 3 | 1 | 1 | 1 | 6 | 0 | — | — | Feb 27, 2015 |
| Denosumab | Phase 3 | Phase 3 | 1 | 1 | 1 | 4 | 0 | — | — | Nov 16, 2009 |
| Fexagratinib | Phase 3 | Phase 3 | 1 | 0 | 1 | 4 | 0 | — | — | Jan 15, 2014 |
| Nogapendekin Alfa Inbakicept | Phase 3 | Phase 3 | 1 | 1 | 1 | 2 | 0 | — | — | May 29, 2026 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.